Clinical trials, Brexit and the question of ‘full alignment’
May 21, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing brexit, clinical trials, feature, pharma
Gene Matthews, Partner at Leigh Day, reviews the tough decisions the UK has to make regarding its position in the …
EMA review confirms risks of Abbvie and Biogen’s Zinbryta outweigh benefits
May 21, 2018Research and Development, Sales and Marketing EMA, Europe, European Commission, PRAC, multiple sclerosis, pharma, zinbryta
The EMA has judged that the benefits offered by Zinbryta (daclizumab), Abbvie and Biogen’s humanised IgG1 monoclonal antibody for the …
Roche’s Hemlibra stakes claim to be haemophilia market leader
May 21, 2018Research and Development, Sales and Marketing Hemlibra, Roche, Shire, biotech, drugs, haemophilia, pharma, pharmaceutical
Hemlibra was widely expected to become the dominant therapeutic for treating haemophilia patients and its latest clinical trial results only …
FDA approves AZ’s Lokelma for hyperkalaemia
May 21, 2018Sales and Marketing AstraZeneca, FDA, Lokelma, hyperkalaemia, pharma
The FDA has revealed its decision to approve AstraZeneca’s oral potassium-removing agent Lokelma (sodium zirconium cyclosilicate) for the treatment of …
Investigation of kickbacks in Greece sputters to halt
May 21, 2018Sales and Marketing Greece, Novartis, biotech, drugs, pharma, pharmaceutical
Greek parliament has decided against investigating allegations of bribery, involving Novartis and numerous high-level former politicians. The case has dominated …
Top Ten most popular articles on Pharmafile.com this week
May 18, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, FDA, Novartis, Takeda, Trump, brexit, pharma, pharmafile, top ten
The year is flying by – it’s another Friday, and that means another Top Ten run-down.Perhaps the biggest story this …
Ebola threat intensifies in DR Congo
May 18, 2018Medical Communications Ebola, MSD, biotech, drugs, pharma, pharmaceutical
The Ebola outbreak in the Democratic Republic of Congo is becoming increasingly serious, after it was confirmed that there was …
Pfizer’s Lyrica achieves endpoint as adjunct in paediatric epilepsy
May 18, 2018Medical Communications, Research and Development FDA, Lyrica, Pfizer, epilepsy, pharma
Pfizer has revealed new Phase 3 data for its oral epilepsy therapy Lyrica (pregbalin) as an adjunctive treatment for partial …
Amgen/Novartis potential blockbuster migraine med gets FDA nod
May 18, 2018Medical Communications, Sales and Marketing Allergan, Amgen, Novartis, biotech, drugs, migraine, pharma, pharmaceutical
The first in a new class of migraine treatments has just received approval from the FDA; Amgen and Novartis’ Aimovig …
Study finds Herceptin use can be halved
May 17, 2018Medical Communications, Research and Development Herceptin, Roche, biosimilars, biotech, drugs, pharma, pharmaceutical
A team of researchers from the University of Cambridge and Warwick Clinical Trials have revealed that Roche’s Herceptin is just …
Living with an undiagnosed condition
May 17, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing feature, patient experience, pharma
Samantha O’Shea explains some of the challenges she faces caring for her son, Ethan, who lives with a debilitating but …
Europe expands approved indication of Amgen’s Repatha in cardiovascular disease
May 17, 2018Sales and Marketing Amgen, Repatha, cardiovascular disease, pharma
Amgen has revealed that its PCSK9 inhibitor Repatha (evolocumab) has received approval from the European Commission in a new indication: …
Ipsen receives European first-line approval for Cabometyx
May 17, 2018Sales and Marketing Cabometyx, biotech, drugs, ipsen, pharma, pharmaceutical
Ipsen has revealed that it has received approval for the use of Cabometyx for first-line use in patients with advanced …
FDA green lights first non-opioid therapy to manage symptoms of opioid withdrawal
May 17, 2018Sales and Marketing FDA, Lucemyra, opioid crisis, opioids, pharma
As the opioid epidemic continues to grip the US as the leading cause of deaths in those under the age …
UK MPs call for Brexit priority over pharma industry
May 17, 2018Medical Communications ABPI, UK government, biotech, drugs, pharma, pharmaceutical
A new report published by the Business, Energy and Industrial Strategy Committee has called for the UK government to ensure …
Roche gets NICE approval for advanced bladder cancer
May 17, 2018Sales and Marketing Roche, biotech, drugs, pharma, pharmaceutical, tecentriq
Though trial results for Tecentriq (atezolizumab) may not necessarily be going Roche’s way, after a combination treatment failure, the treatment …
Lilly’s galcanezumab soars in episodic cluster headache, but fails in chronic form
May 16, 2018Research and Development Eli Lilly, galcanezumab, headache, migraine, pharma
Eli Lilly has released new Phase 3 results for its CGRP inhibitor galcanezumab in the treatment of episodic cluster headache, …
Novartis’ top lawyer retires from role over botched Trump deal
May 16, 2018Medical Communications, Research and Development Michael Cohen, Novartis, Trump, pharma
The saga of Novartis’ ill-advised $1.2 million deal with US President Donald Trump’s lawyer Michael Cohen continues to unfold as …
Pfizer scores approval for first Epogen/Procrit biosimilar in the US
May 16, 2018Research and Development, Sales and Marketing Epogen, Pfizer, Procrit, Retacrit, biosimilar, pharma FDA
Pfizer’s Retacrit (epoetin alfa-epbx), a biosimilar version of Amgen’s Epogen and Janssen’s Procrit, has been approved for use in the …
How to treat colds? Target the person, not the virus
May 15, 2018Research and Development biotech, common cold, drugs, pharma, pharmaceutical
Researchers from Imperial College London have discovered how to interfere with one of the building blocks that allows the common …
Latest content
Aiforia deal to expand access to pathology AI
SMC accepts atogepant for acute migraine treatment in Scotland
New CCO Ogburn joins Cori Clinical
Claris reports visual acuity gains with experimental LSCD treatment
Amphista doses first patient in AML trial of protein degrader
